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SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid
leukemia-like disease and for normal hematopoietic stem cell
function
N Hansen1, H Ågerstam1, M Wahlestedt2, N Landberg1, M Askmyr1, M Ehinger3, M Rissler1, H Lilljebjo¨rn1, P Johnels1, J Ishiko4,
JV Melo4,5, WS Alexander6,7, D Bryder2, M Ja¨ra˚s1 and T Fioretos1
Suppressor of cytokine signaling 2 (SOCS2) is known as a feedback inhibitor of cytokine signaling and is highly expressed in primary
bone marrow (BM) cells from patients with chronic myeloid leukemia (CML). However, it has not been established whether SOCS2 is
involved in CML, caused by the BCR/ABL1 fusion gene, or important for normal hematopoietic stem cell (HSC) function. In this study,
we demonstrate that although Socs2 was found to be preferentially expressed in long-term HSCs, Socs2-deﬁcient HSCs were
indistinguishable from wild-type HSCs when challenged in competitive BM transplantation experiments. Furthermore, by using a
retroviral BCR/ABL1-induced mouse model of CML, we demonstrate that SOCS2 is dispensable for the induction and propagation of
the disease, suggesting that the SOCS2-mediated feedback regulation of the JAK/STAT pathway is deﬁcient in BCR/ABL1-induced
CML.
Leukemia (2013) 27, 130–135; doi:10.1038/leu.2012.169
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INTRODUCTION
Chronic myeloid leukemia (CML) arises from hematopoietic
stem cells (HSCs) that have acquired a reciprocal t(9;22)
translocation, creating the BCR/ABL1 fusion gene. The P210 BCR/
ABL1 fusion protein has been described to initiate signaling
through several downstream pathways such as STAT5, PI3K,
AKT, RAS and WNT.1 However, only a few downstream mediators
have so far been thoroughly studied in vivo in the context of
BCR/ABL1-mediated induction of CML, using mice deﬁcient for the
speciﬁc genes. Such studies have demonstrated that interleukin
3 (Il3), granulocyte macrophage colony stimulating factor (Csf2)
and Cbl are dispensable for a BCR/ABL1-induced CML-like
disorder.2,3 In contrast, Alox5 was reported to be a critical
regulator of leukemic stem cells in BCR/ABL1-induced CML.4,5
Moreover, cells deﬁcient for both Stat5a and Stat5b lack the
capacity to develop disease and JAK/STAT signaling has emerged
as a pivotal pathway by which BCR/ABL1 elicits its transforming
effects.6–9
The STAT5-induced suppressor of cytokine signaling 2 (SOCS2),
a known feedback inhibitor of the JAK/STAT pathway, has
previously been found upregulated in the advanced stages of
CML and to become downregulated following imatinib treat-
ment in both CML cell lines and primary cells.10–15 In addition,
SOCS2 was recently identiﬁed as one of the core genes in gene
expression signatures shared between normal HSC and acute
myeloid leukemia leukemic stem cells, with both signatures
being associated with worse clinical outcome in acute
myeloid leukemia.16 Collectively, these ﬁndings suggest that
SOCS2 may be important for both normal HSC function and
BCR/ABL1-induced leukemia. SOCS2 is one of eight members (CIS
and SOCS1–7) of the SOCS gene family which all have both SH2
and SOCS box domains in common.17 This family of proteins is
normally expressed upon stimulation with various cytokines and
has mainly been characterized as feedback inhibitors of cytokine-
induced signaling.18–20 However, their function is more complex,
as activating properties also have been suggested for SOCS2.21–24
SOCS2 is present in several tissues and involved in the regulation
of several cytokines such as GH, IGF1, IL2, IL3 and EPO, with both
inhibitory and enhancing properties through other SOCS proteins
and receptor-JAK complexes.23–25 The most striking feature of
Socs2-deﬁcient mice is gigantism caused by an STAT5B-dependent
increase of sensitivity to GH signaling.26,27 However, the steady-
state hematopoiesis of Socs2-deﬁcient mice appears normal.26
In this study, we found that although Socs2 was preferentially
expressed in the long-term HSC (LT-HSC) population, it was
dispensable for normal HSC function as determined by compe-
titive stem cell transplantation. To clarify the role of SOCS2
upregulation in CML, we evaluated BCR/ABL1-induced CML-like
disease from Socs2 / versus Socs2þ /þ primitive bone marrow
(BM) cells. Both groups developed indistinguishable CML-like
disorders with similar survival curves, spleen weights, white blood
cell counts and levels of STAT5 phosphorylation. Collectively, our
data demonstrate that SOCS2 is dispensable for normal HSC
function and for BCR/ABL1-mediated induction of CML.
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All animal experiments were approved by the local ethics committee in
Lund, Sweden. Generation of the Socs2 / mice in C57BL/6 background
has been described previously.26 The primers used for genotyping were
50-CGAGCTCAGTCAAACAGGTAGG-30 and 50-GCTTTCAGATGTAGGGTGCTTT
CC-30 to detect Socs2, and 50-GCAGACGATGGTGCAGGATATCC-30 and 50-GG
ATCGACAGATTTGATCCAGC-30 to detect the b-galactosidase gene replacing
Socs2.28 B6SJL mice and F1 crossings of C57BL/6xB6SJL were used as
recipients and for competitor/support cells in the transplantations.
Analysis of Socs2 expression from global gene expression data
To study the gene expression pattern of Socs2 in various sub-populations
of normal mouse hematopoietic cells, the raw CEL ﬁles for the data set
GSE14833 were downloaded from gene expression omnibus (http://
www.ncbi.nlm.nih.gov/geo/). Gene expression values were normalized
using GCRMA.29 The mean expression value for the probe sets 1449109_at
and 1418507_s_at was used to determine Socs2 expression.
Flow cytometry analysis and sorting
Fluorescence-activated cell sorting (FACS) analysis was performed with
either FACS Canto II or FACS Aria (Becton Dickinson, Franklin Lakes,
NJ, USA). All cells sorted for HSC analysis were freshly extracted from
Socs2þ /þ or Socs2 / mice and stained with several antibodies, to
identify various sub-populations. The stem cell population used for
expression analysis of Socs2 was deﬁned as lineage negative for B220,
CD3, Mac1, Gr-1, Ter.119 and, in addition, IL7Rac-kitþSca1þCD34
ﬂt3 . The common myeloid progenitors were deﬁned as c-kitþSca-1
CD34þCD16/32mid. The HSCs used for transplantation were sorted as
above but with the additional SLAM markers CD150þCD48 . Antibodies
used were purchased either from Biolegend (San Diego, CA, USA) or
eBioscience (San Diego, CA, USA).
For multicolor analysis of lineage distribution, we used antibodies
against CD19 and CD4 (eBioscience); TER.119, CD8a, CD11b, CD45.1 and
CD45.2 (Biolegend); CD45R/B220, Ly-6G/Ly-6C and Gr-1 (Becton Dickinson).
HSC transplantation
B6SJL recipient mice were lethally irradiated (900 cGy) 18 h before
transplantation and Ciproﬂoxacin was supplemented with the drinking
water following transplantation. BM cells were harvested and pooled from
ﬁve age and sex matched Socs2 / and Socs2þ /þ donors, respectively.
For each recipient, 200 lineageSca-1þc-kitþCD34ﬂt3CD150þCD48
cells (LT-HSC) were sorted and injected intravenously together with
300 000 C57BL/6xB6SJL competitor cells. Repopulation was calculated as
(proportion CD45.2þ cells)/(proportion CD45.2þ cellsþproportion
CD45.1.2þ cells). Lineage distribution was analyzed within the donor
population, determined by CD45.2 expression. Approximately 3 106 BM
cells from each primary recipient were transplanted into two lethally
irradiated secondary recipients.
P210 transduction and transplantation model
The retroviral construct MSCV-BCR/ABL1-IRES-GFP was kindly provided by
Prof. Connie Eaves together with a control vector expressing only GFP
(MIG).30 Ecotropic viral particles were produced by transient transfection
into 293T cells. The transductions and transplantation experiments were
performed essentially as described by Li et al.31 In brief, matched Socs2þ /þ
and Socs2 / donors were killed and c-kitþ cells were isolated using midi
MACS and anti-CD117 micro beads (Miltenyi Biotech, Bergisch Gladbach,
Germany). A total of 400 000 cells per recipient were prestimulated in
StemSpan serum-free expansion medium (Stemcell Technologies,
Grenoble, France) supplemented with 50 ng/ml murine SCF, 10 ng/ml
murine IL-3, 50 ng/ml human IL-6 (Peprotech, Rocky Hill, NJ, USA), for
48 h. Transductions were performed by preloading viral particles using
Retronectin (Takara bio Inc., Otsu, Japan). Cells for transplantation were
harvested B18 h after transduction, washed, and injected in bulk via the
tail vein along with 100 000 freshly isolated supporting cells from whole
BM. The transduction efﬁciency obtained was between 10 and 15% of the
transplanted cells, as determined by FACS analysis of GFP on in-vitro
cultured cells, 2 days after the transduction. Recipient mice were irradiated
as described above and transplanted mice received Ciproﬂoxacin with the
drinking water throughout experiment.
Blood analysis and histopathology
Untreated mice were bled from tail veins to determine steady-state blood
cell counts in Socs2 / mice, and mice transplanted with transduced cells
were bled around 15 days after transplantation. Blood cell counts were
analyzed on ABX Micros 60 (Horiba ABX, Montpellier, France). Femur and
spleen from diseased mice were conserved in 4% formaldehyde, parafﬁn
embedded and sectioned before staining with hematoxylin and eosin as
previously described.32
Taqman PCR and western blot
Whole BM cells were extracted from transplanted mice after euthanasia
and the BM cells were viably frozen. Freshly isolated HSCs and common
myeloid progenitors were sorted as described above and cryopreserved,
viable and GFP-expressing cells were sorted from diseased mice (from MIG
control mice all myeloid cells were sorted due to lack of GFP expression).
RNA was extracted from the sorted cells using the RNeasy micro kit
(Qiagen, Hilden, Germany). Gene expression was analyzed by real-time
quantitative reverse-transcriptase PCR (RT-QPCR) using predesigned Taq-
Man probes for all known members of the Socs gene family and murine
Actb or Gapdh as endogenous controls (Applied Biosystems, Foster City,
CA, USA). RT-QPCR was performed on an ABI Prism 7500 analyzer (Applied
Biosystems) and ddCT values were calculated as described.33 Western blot
analysis to detect STAT5A/B proteins and STAT5 tyrosine phosphorylation
was performed as described, using 150 000 sorted PIGFPþMac1þ cells.32
The membrane was stripped after P-STAT5 detection and relabeled to
detect the STAT5 protein.
Intracellular ﬂow cytometric analysis
Cells were harvested 48 h after a P210 transduction was made, as
described above. Fc receptors were blocked with unlabeled CD16/CD32
antibodies (Becton Dickinson). Fixation and permeabilization of cells were
performed using the Cytoﬁx/cytoperm kit (Becton Dickinson) and the cells
were stained with antibodies detecting phosphorylation of STAT5 or STAT3
(Becton Dickinson).
RESULTS
Socs2 expression is high in HSCs
To study the role of SOCS2 in normal hematopoiesis, we ﬁrst
investigated the gene expression pattern of Socs2 in various
hematopoietic lineages using public gene expression data.
Interestingly, Socs2 was found highly expressed in normal LT-
HSC relative to other hematopoietic lineages (Figure 1a). Valida-
tions using RT-QPCR showed that the Socs2 expression was about
30 times higher in HSCs compared with Lin cells and common
myeloid progenitors (Figure 1b), implying that SOCS2 may have a
role in HSC function.
Socs2-deﬁcient mice display normal HSC function
In accordance with previous ﬁndings demonstrating that mice
lacking Socs2 have normal steady-state hematopoiesis,26 the
Socs2-deﬁcient mice had normal peripheral blood cell counts.
Although steady-state hematopoiesis was unaffected in Socs2-
deﬁcient mice, it could still be envisioned that SOCS2, due to its
role in cytokine signaling, could have an important role in
regulating HSC function under conditions when the
hematopoietic system is stressed. Thus, to investigate whether
loss of SOCS2 affects the function of HSCs, we performed
competitive BM transplantations, in which Socs2-deﬁcient BM
cells were challenged with wild-type competitor cells. At steady
state, no signiﬁcant difference in stem cell frequency as
determined by LSKCD150þCD48 or LSKCD34ﬂt3 was
found between Socs2 / and Socs2þ /þ BM cells (Figure 2a).
Furthermore, we observed no difference in repopulation between
Socs2þ /þ and Socs2 / cells in either primary or secondary
recipients, suggesting that SOCS2, also under conditions of
hematopoietic stress, is dispensable for both short- and long-
term HSC function (Figures 2b and c; Supplementary Figure 1).
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SOCS2 is dispensable for BCR/ABL1-induced CML-like disease
in mice
As a regulator of JAK/STAT mediated signaling, SOCS2 has been
suggested to have a role in both BCR/ABL1 and JAK2 V617F-
mediated myeloid leukemogenesis.11,13,34 The ﬁndings that loss of
SOCS2 did not have any dramatic effects on steady-state
hematopoiesis or HSC function, allowed us to examine the role
of BCR/ABL1-mediated CML-like disease in Socs2 / cells without
confounding factors attributed to effects of Socs2 deﬁciency on
normal HSC function. By using the BCR/ABL1 retroviral
transduction and transplantation model previously described,31
c-kitþ BM cells were transduced and transplanted into lethally
irradiated mice, to examine disease progression in vivo. About
3 weeks after transplantation, most mice receiving BCR/ABL1-
expressing cells developed CML-like symptoms similar to previous
reports,4,31 and had to be euthanized shortly thereafter (Figure 3a).
No difference in disease latency between mice receiving either
Socs2þ /þ or Socs2 / cells was observed. Furthermore, when
peripheral blood was analyzed 14–16 days after transplantation,
both Socs2þ /þ and Socs2 / mice had elevated white blood cell
and platelet counts compared with controls (Figure 3b and data
not shown). When euthanized due to disease symptoms, mice
from both groups suffered from severe splenomegaly (Figure 3c)
and FACS analysis showed that most had an expansion of myeloid
GFPþ cells in the BM (Figure 3d). To further address whether the
Socs2þ /þ and Socs2 / cells caused different leukemic pheno-
types, histopathologic examinations were performed on femurs
and spleens from diseased mice. In the BM, BCR/ABL1 caused
similar phenotypes in Socs2þ /þ and Socs2 / mice with foci of
histocytes, enlarged sinusoids, and reduced erythropoiesis com-
pared with the MIG control (Figure 4a and data not shown). All
mice with disease had markedly enlarged spleens with inﬁltration
of granulocytes in various maturation stages (Figure 4b and data
not shown). In a number of enlarged spleens, we also found focal
regions with blasts in both Socs2þ /þ and Socs / transplanted
recipients (data not shown). In summary, the histopathological
features were clearly pathologic but recipient mice, transplanted
with BCR/ABL1 transduced Socs2þ /þ or Socs2 / cells, were
similar.
Expression analysis of all Socs family members does not suggest
compensatory expression of other Socs genes
In BCRABL1-expressing cells from diseased mice, the Socs2
expression was determined to be about 10-fold increased
(Figure 5a). Since different SOCS proteins can interact in both
enhancing and inhibitory ways and in part have overlapping
functions, it is possible that compensatory upregulation of other
Socs genes might compensate for the loss of SOCS2 in BCR/ABL1
transformed cells.21,35 To test this hypothesis, we sorted GFPþ
cells from diseased mice transplanted with Socs2þ /þ or Socs2 /
cells, as well as fresh common myeloid progenitors from
Socs2þ /þ and Socs2 / mice, and measured the expression of
individual members of the Socs gene family. In this analysis, no
increase in gene expression was observed throughout the Socs
gene family in Socs2-deﬁcient cells (Figure 5b; Supplementary
Figure 2), suggesting that other SOCS family members do not
compensate for the lack of SOCS2. SOCS2 is known to act as a
feedback inhibitor of STAT5 signaling, suggesting that a BCR/ABL1-
expressing cell with functional SOCS2 should have lower STAT5
phosphorylation compared with Socs2 / cells. However, similar
levels of STAT5 phosphorylation were detected in both Socs2þ /þ
and Socs2 / cells from leukemic mice, indicating that the effect
of BCR/ABL1 bypasses SOCS2-mediated feedback inhibition of
STAT5 (Figure 5c). Because also STAT3 has been suggested to be
phosphorylated by BCR/ABL1,36 we measured STAT3 and STAT5
Figure 2. (a) Frequency of HSCs (in percent) determined by FACS
phenotyping of BM cells from Socs2þ /þ and Socs2 / mice. The
LT-HSC population was defined by the markers LSKCD34flt3 (top
panel) or by LSK and the alternative SLAM markers CD150þCD48
(lower panel). (b, c) BM reconstitution in peripheral blood at 4 (a)
and 18 weeks (b) after competitive BM transplantation. Repopula-
tion is shown as the percentage of donor cells compared with the
total amount of donor and competitor cells. Bars indicating lineage
distribution show the donor cell population.
Figure 1. (a) Comparison of Socs2 expression in various FACS sorted hematopoietic BM populations, analyzed by Affymetrix microarray.
Expression data were acquired from the Gene Expression Omnibus data set GSE 14833 and normalized using the GCRMA method (see
Materials and Methods). The expression values provided represent relative Socs2 expression values for the different cell populations.
(b) Validation by RT-QPCR confirmed that Socs2 is expressed at high levels in HSCs compared with other hematopoietic cell populations. Socs2
expression is presented as fold change compared with the Socs2 expression in lin cells, with Gapdh as endogenous control.
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phosphorylation in BCR/ABL1 transduced Socs2þ /þ and Socs2 /
cells by intracellular FACS. Both the Socs2þ /þ and Socs2 / cells
had equally increased STAT5 phosphorylation compared with MIG
control, while no increase in STAT3 phosphorylation was observed
(Supplementary Figure 3).
DISCUSSION
As a modulator of the JAK/STAT signaling pathway, a pathway
with a demonstrated role in CML, the strong upregulation of
SOCS2 in CML has raised the question whether SOCS2 is involved
in BCR/ABL1-induced transformation or whether it is part of an
inadequate feedback loop.6,11–15 SOCS2 has been suggested to
have a role as feedback inhibitor in certain types of cancers, but its
role may be more complex, as it is variably reported as having
both enhancing and inhibitory functions in normal cytokine-
induced signaling.21–24,37 As we observed a strong upregulation of
Socs2 in mouse LT-HSC, in accordance with recent ﬁndings in
human candidate HSC,16 we ﬁrst explored the role of SOCS2 in
normal HSCs using competitive BM transplantation experiments.
Figure 3. (a) Survival of mice after transplantation of BCR/ABL1-expressing cells. Six out of nine mice transplanted with empty MIG vector were
killed at day 28 to extract organs for analysis. (b) White blood cell counts in peripheral blood, measured 14–16 days after transplantation.
(c) Spleen weight of leukemic mice at euthanasia. Statistical significance with a P value o0.001 is indicated by ***. (d) Representative
FACS analysis of BM cells from a mouse with BCR/ABL1-induced disease. The table summarizes the dominating lineage commitment of
GFPþ -expressing cells in BM. Gr-1 or Mac-1 was used as myeloid markers and B220 to detect B cells.
Figure 4. Histopathologic staining of BM and spleen after disease onset. (a) Hematoxylin eosin staining of BM sections showing increased
granulopoiesis and enlarged sinusoids both in mice transplanted with Socs2þ /þ and Socs2 / cells compared with MIG. (b) Hematoxylin
eosin staining of spleen with marked pathology, including severe infiltration of hematopoietic cells at various maturation stages, after
Socs2þ /þ and Socs2 / transplants.
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Although it could be speculated that high expression of Socs2 in
LT-HSCs would serve as a brake, keeping this cell population
quiescent due to insensitivity to stimulating growth factors,
Socs2 / HSCs showed equal repopulation properties both
short-term and long-term, as wild-type HSCs. Although we
cannot fully exclude that Socs2 deﬁciency may have a subtle
effect on HSCs, our ﬁndings strongly suggest that Socs2 is not
critical for normal HSC function.
To evaluate the potential role of SOCS2 in CML, we used the
previously established retroviral BCR/ABL1 transduction and
transplantation model,31 comparing disease manifestation
derived from Socs2þ /þ versus Socs2 / cells. Mice
transplanted with either donor types showed similar disease
onset, displayed similar symptoms such as elevated white blood
cell counts, splenomegaly and expansion of myeloid cells, and had
similar survival curves. These ﬁndings demonstrate that SOCS2 is
not crucial for disease initiation and propagation in this model of
CML. However, the rapid disease course and the short survival
times clearly pose a potential problem as weak phenotypes may
be overlooked. In an attempt to investigate if a disease model with
longer disease latency could be established, we also transduced
and transplanted fewer cells. However, transplantation of fewer
MIG-BCR/ABL1 transduced cells resulted in similar disease latency,
but with a reduced penetrance with only a few recipients
developing a CML-like disease (data not shown). Thus, using this
well-established model of murine CML-like disease, it is difﬁcult to
entirely exclude subtle effects of SOCS2 in the initiation and
progression of CML.
It is also well possible that functional redundancy could exist
between different members of the Socs gene family, which could
explain the lack of phenotype in this model. However, examining
the expression levels of other Socs family members in Socs2-
deﬁcient cells, we did not ﬁnd any compensatory upregulation of
the other Socs family members. This indicates that functional
redundancy involving other Socs family members is an unlikely
cause of the unaltered disease course in mice receiving BCR/ABL1-
transduced Socs2 / BM cells. However, both CISH and SOCS3
have previously been reported to be upregulated in CML
patients.13 Thus, future studies combining silencing of additional
Socs members will be needed to ultimately clarify this issue.
BCR/ABL1 is well known to activate several downstream
signaling mediators such as STAT5.6,38 The transcription of Socs2
is normally induced by STAT5 activation, and the SOCS2 protein
typically acts as a feedback inhibitor upstream of STAT5 by
targeting the interaction between JAK and cell surface receptors
such as the GH receptor.10,27,34,39 In this study, we demonstrate
that SOCS2 is dispensable for BCR/ABL1-mediated induction of
CML, despite Socs2 being highly upregulated by BCR/ABL1. Our
ﬁnding that cells expressing BCR/ABL1 have equal STAT5
phosphorylation independently of Socs2 deﬁciency supports a
hypothesis that SOCS2 fails to act as a feedback inhibitor of the
JAK2/STAT5 pathway in the context of BCR/ABL1 signaling.
Because BCR/ABL1 has been shown to activate both JAK2 and
STAT5 directly,8,9,36 it seems reasonable that the upstream
inhibition of this pathway provided by SOCS2 would have
minimal effects on BCR/ABL1-induced signaling, which is
consistent with our results.
In conclusion, we have demonstrated that SOCS2 is dispensable
for both normal HSC function and CML-like disease. These ﬁndings
support the hypothesis that Socs2 upregulation by BCR/ABL1 is
caused by an inadequate or non-functional feedback loop induced
by BCR/ABL1.
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Figure 5. Gene expression analysis and western blot of STAT5 phosphorylation of BM cells from diseased mice. The cells were sorted before
analysis, selecting GFPþMac1þ leukemic Socs2þ /þ or Socs2 / cells and Mac1þ MIG control cells. (a) Fold difference in expression of Socs2
in leukemic Socs2þ /þ cells relative to empty MIG control, with Actb as endogenous control. Transduced cells show increased expression of
Socs2 in BCR/ABL1-expressing cells. Statistical significance with a P valueo0.05 is indicated by *. (b) Expression of individual members of the
Socs gene family in Socs2þ /þ versus Socs2 / cells. The expression of each Socs family member in Socs2 / cells is presented as fold change
relative to Socs expression in the Socs2þ /þ cells using Actb as endogenous control. (c) Western blot analysis of total STAT5 (upper panel) and
phosphorylated STAT5 (lower panel) in sorted GFPþ bone marrow cells from one control MIG mouse and two Socs2 / and Socs2þ /þ mice,
respectively.
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